Southborough, United States
NanoDx, Inc. is a pioneering force in the medical device sector, strategically positioned within Biotechnology, Health Care, and Medical Devices industries. Established in 2010 and headquartered in the United States, the company has made significant strides in developing breakthrough point-of-care diagnostic solutions.
Utilizing its proprietary nanowire biosensor platform, the NanoDx™ System is designed to deliver ultra-fast and highly accurate diagnostic results in under two minutes from minimal blood or saliva samples. Key collaborations with notable entities like IBM and SkyWater Technologies have enabled NanoDx to incorporate a high-volume, cost-effective CMOS process into its advanced platform. The focus is initially on critical applications like traumatic brain injury (TBI) and Covid-19, with the potential to expand into other areas such as stroke and sepsis.
Although not yet reviewed by the FDA and currently for research use only, NanoDx, Inc. has garnered substantial investor interest, including a recent $18.00M Series C investment led by Shepherd Kaplan Krochuk on June 29, 2020. Their competitive edge is marked by the system's ease-of-use, rapid diagnostic capability, and high sensitivity, positioning it as a strong contender for future market leadership.
HemoSonics
